These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

249 related articles for article (PubMed ID: 8899968)

  • 1. Cryptococcus neoformans: paradigm for the role of antibody immunity against fungi?
    Pirofski LA; Casadevall A
    Zentralbl Bakteriol; 1996 Aug; 284(4):475-95. PubMed ID: 8899968
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunoglobulin G3 blocking antibodies to the fungal pathogen Cryptococcus neoformans.
    Nussbaum G; Yuan R; Casadevall A; Scharff MD
    J Exp Med; 1996 Apr; 183(4):1905-9. PubMed ID: 8666947
    [TBL] [Abstract][Full Text] [Related]  

  • 3. An anti-beta-glucan monoclonal antibody inhibits growth and capsule formation of Cryptococcus neoformans in vitro and exerts therapeutic, anticryptococcal activity in vivo.
    Rachini A; Pietrella D; Lupo P; Torosantucci A; Chiani P; Bromuro C; Proietti C; Bistoni F; Cassone A; Vecchiarelli A
    Infect Immun; 2007 Nov; 75(11):5085-94. PubMed ID: 17606600
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cryptococcus neoformans infection can elicit protective antibodies in mice.
    Mukherjee J; Scharff MD; Casadevall A
    Can J Microbiol; 1994 Oct; 40(10):888-92. PubMed ID: 8000967
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Both Th1 and Th2 cytokines affect the ability of monoclonal antibodies to protect mice against Cryptococcus neoformans.
    Beenhouwer DO; Shapiro S; Feldmesser M; Casadevall A; Scharff MD
    Infect Immun; 2001 Oct; 69(10):6445-55. PubMed ID: 11553589
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Protective and nonprotective human immunoglobulin M monoclonal antibodies to Cryptococcus neoformans glucuronoxylomannan manifest different specificities and gene use profiles.
    Maitta RW; Datta K; Chang Q; Luo RX; Witover B; Subramaniam K; Pirofski LA
    Infect Immun; 2004 Aug; 72(8):4810-8. PubMed ID: 15271943
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Monoclonal antibodies reveal additional epitopes of serotype D Cryptococcus neoformans capsular glucuronoxylomannan that elicit protective antibodies.
    Mukherjee J; Kozel TR; Casadevall A
    J Immunol; 1998 Oct; 161(7):3557-68. PubMed ID: 9759877
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Protective and nonprotective monoclonal antibodies to Cryptococcus neoformans originating from one B cell.
    Mukherjee J; Nussbaum G; Scharff MD; Casadevall A
    J Exp Med; 1995 Jan; 181(1):405-9. PubMed ID: 7807020
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Polysaccharides, mimotopes and vaccines for fungal and encapsulated pathogens.
    Pirofski LA
    Trends Microbiol; 2001 Sep; 9(9):445-51. PubMed ID: 11553457
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mechanism of action of antibody to capsular polysaccharide in Cryptococcus neoformans infection.
    Feldmesser M; Casadevall A
    Front Biosci; 1998 Feb; 3():d136-51. PubMed ID: 9445465
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A cryptococcal capsular polysaccharide mimotope prolongs the survival of mice with Cryptococcus neoformans infection.
    Fleuridor R; Lees A; Pirofski L
    J Immunol; 2001 Jan; 166(2):1087-96. PubMed ID: 11145689
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antibodies to Cryptococcus neoformans glucuronoxylomannan enhance antifungal activity of murine macrophages.
    Mukherjee S; Lee SC; Casadevall A
    Infect Immun; 1995 Feb; 63(2):573-9. PubMed ID: 7822024
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antibody-mediated protection in mice with lethal intracerebral Cryptococcus neoformans infection.
    Mukherjee J; Pirofski LA; Scharff MD; Casadevall A
    Proc Natl Acad Sci U S A; 1993 Apr; 90(8):3636-40. PubMed ID: 8475112
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Analysis of human monoclonal antibodies elicited by vaccination with a Cryptococcus neoformans glucuronoxylomannan capsular polysaccharide vaccine.
    Pirofski L; Lui R; DeShaw M; Kressel AB; Zhong Z
    Infect Immun; 1995 Aug; 63(8):3005-14. PubMed ID: 7622223
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Protective murine monoclonal antibodies to Cryptococcus neoformans.
    Mukherjee J; Scharff MD; Casadevall A
    Infect Immun; 1992 Nov; 60(11):4534-41. PubMed ID: 1398966
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy of immune sera from human immunoglobulin transgenic mice immunized with a peptide mimotope of Cryptococcus neoformans glucuronoxylomannan.
    Maitta RW; Datta K; Pirofski LA
    Vaccine; 2004 Sep; 22(29-30):4062-8. PubMed ID: 15364457
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In vitro and in vivo stability of a Cryptococcus neoformans [corrected] glucuronoxylomannan epitope that elicits protective antibodies.
    Cleare W; Cherniak R; Casadevall A
    Infect Immun; 1999 Jun; 67(6):3096-107. PubMed ID: 10338526
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mouse-human immunoglobulin G1 chimeric antibodies with activities against Cryptococcus neoformans.
    Zebedee SL; Koduri RK; Mukherjee J; Mukherjee S; Lee S; Sauer DF; Scharff MD; Casadevall A
    Antimicrob Agents Chemother; 1994 Jul; 38(7):1507-14. PubMed ID: 7979280
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antibodies elicited by a Cryptococcus neoformans-tetanus toxoid conjugate vaccine have the same specificity as those elicited in infection.
    Casadevall A; Mukherjee J; Devi SJ; Schneerson R; Robbins JB; Scharff MD
    J Infect Dis; 1992 Jun; 165(6):1086-93. PubMed ID: 1583327
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunoglobulin G monoclonal antibodies to Cryptococcus neoformans protect mice deficient in complement component C3.
    Shapiro S; Beenhouwer DO; Feldmesser M; Taborda C; Carroll MC; Casadevall A; Scharff MD
    Infect Immun; 2002 May; 70(5):2598-604. PubMed ID: 11953401
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.